Article

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants

2021-02-03

Abstract excerpt

SARS-CoV-2 has infected millions of people globally and continues to undergo evolution. Emerging variants can be partially resistant to vaccine induced immunity and therapeutic antibodies, emphasizing the urgent need for accessible, broad-spectrum therapeutics. Here, we report a comprehensive study of ensovibep, the first trispecific clinical DARPin candidate, that can simultaneously engage all three units of the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e103fd88-d973-51b7-846a-485ab0737d26
DOI: 10.1101/2021.02.03.429164

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variantsDOI 10.1101/2021.02.03.429164Read

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variantsSemantic proximity Read

Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidatesSemantic proximity Read

A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.Semantic proximity Read

Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD bindingSemantic proximity Read

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistanceSemantic proximity Read

Biparatopic sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug resistanceSemantic proximity Read

Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodiesSemantic proximity Read

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variantSemantic proximity Read

Evaluating SARS-CoV-2 Antibody Resilience via Prediction and Design of Escape Viral VariantsSemantic proximity Read

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 VariantsSemantic proximity Read

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.Semantic proximity Read

Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In VivoSemantic proximity Read